Back HCV Treatment

AASLD 2015: New AbbVie Hepatitis C Combination Cures 93%-97% with Genotype 3

A combination of 2 experimental direct-acting antivirals developed by AbbVie cured 93%-97% of people with genotype 3 hepatitis C after a 12-week course of treatment, Paul Kwo from Indiana University School of Medicine reported at the 2015 AASLD Liver Meeting this week in San Francisco.


Read more: